Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2127304
Abstract: Dupilumab is a monoclonal antibody that inhibits the action of interleukin-4 and interleukin-13. Since FDA approval in 2017, dupilumab has revolutionized the treatment of moderate-tosevere atopic dermatitis (AD) and has gained approval for additional indications.… read more here.
Keywords: prescription patterns; cost prescription; utilization; utilization cost ... See more keywords